NASDAQ:ARPO - Aerpio Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.38
  • Forecasted Upside: -95.43 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$30.07
▼ -1.79 (-5.62%)

This chart shows the closing price for ARPO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aerpio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARPO

Analyst Price Target is $1.38
▼ -95.43% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Aerpio Pharmaceuticals in the last 3 months. The average price target is $1.38, with a high forecast of $2.00 and a low forecast of $0.75. The average price target represents a -95.43% upside from the last price of $30.07.

This chart shows the closing price for ARPO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Aerpio Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/8/2021HC WainwrightUpgradeNeutral ➝ BuyHigh
3/15/2021HC WainwrightReiterated RatingHoldMedium
12/14/2020HC WainwrightReiterated RatingNeutral$1.00 ➝ $0.75High
12/9/2020BTIG ResearchInitiated CoverageBuy$2.00High
9/17/2020HC WainwrightReiterated RatingHold$1.00High
8/13/2020HC WainwrightBoost Price TargetNeutral$0.75 ➝ $1.00High
6/25/2020HC WainwrightBoost Price TargetNeutral$0.50 ➝ $0.75High
5/28/2020HC WainwrightReiterated RatingHold$0.50High
2/10/2020HC WainwrightReiterated RatingHold$0.50Low
10/21/2019HC WainwrightSet Price TargetHold$0.50Low
8/9/2019HC WainwrightReiterated RatingHold$0.50Medium
6/12/2019HC WainwrightReiterated RatingNeutralLow
6/12/2019HC WainwrightInitiated CoverageNeutral$0.50Low
5/10/2019HC WainwrightReiterated RatingHoldHigh
4/5/2019HC WainwrightReiterated RatingHoldLow
3/19/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
3/18/2019GuggenheimDowngradeBuy ➝ NeutralHigh
3/18/2019National SecuritiesDowngradeBuy ➝ NeutralN/A
3/6/2019HC WainwrightReiterated RatingBuyLow
3/5/2019Cantor FitzgeraldSet Price TargetBuy$4.00Low
2/11/2019Cantor FitzgeraldSet Price TargetBuy$4.00Low
1/18/2019Cantor FitzgeraldReiterated RatingOverweightMedium
1/18/2019Cantor FitzgeraldInitiated CoverageOverweight$4.00High
11/8/2018HC WainwrightSet Price TargetBuy$4.50Low
10/29/2018HC WainwrightSet Price TargetBuy$4.50Low
9/19/2018GuggenheimInitiated CoverageBuy$5.00High
8/15/2018HC WainwrightSet Price TargetBuy$4.50High
7/23/2018Needham & Company LLCInitiated CoverageBuy$5.00Low
4/18/2018HC WainwrightInitiated CoverageBuy$5.00High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aerpio Pharmaceuticals logo
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Read More

Today's Range

Now: $30.07
Low: $30.00
High: $32.65

50 Day Range

MA: $13.21
Low: $1.00
High: $32.66

52 Week Range

Now: $30.07
Low: $0.95
High: $34.50

Volume

53,977 shs

Average Volume

5,147,753 shs

Market Capitalization

$1.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Aerpio Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Aerpio Pharmaceuticals in the last year: BTIG Research, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ARPO.

What is the current price target for Aerpio Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Aerpio Pharmaceuticals in the last year. Their average twelve-month price target is $1.38, suggesting a possible downside of 95.8%. BTIG Research has the highest price target set, predicting ARPO will reach $2.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $0.75 for Aerpio Pharmaceuticals in the next year.
View the latest price targets for ARPO.

What is the current consensus analyst rating for Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARPO will outperform the market and that investors should add to their positions of Aerpio Pharmaceuticals.
View the latest ratings for ARPO.

What other companies compete with Aerpio Pharmaceuticals?

How do I contact Aerpio Pharmaceuticals' investor relations team?

Aerpio Pharmaceuticals' physical mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The official website for Aerpio Pharmaceuticals is www.aerpio.com.